Main conclusion
Genetic ablation of the growth-hormone receptor in 12-month-old mice extended lifespan in both sexes. The model addresses an important biological question: whether later-life modulation of the GH-IGF-1 axis can still alter aging. It is not a human therapy.
What was studied
In males, despite greater adiposity, insulin sensitivity improved and age-related deterioration in neuromuscular performance and bone microarchitecture was reduced. Single-nucleus liver sequencing showed sex-specific transcriptional remodeling, including feminization of part of the male hepatocyte program.
Key limitations
This was a controlled genetic experiment in mice. Pharmacological suppression in humans could behave differently and impair muscle, bone, metabolism, or quality of life. No human trial tested a GH-receptor antagonist as a longevity treatment.
What this means in practice
The study supports further research on GH-IGF-1 biology, not self-suppression of GH or avoidance of indicated treatment for true deficiency.
Source
Aging Cell, 2026. DOI: https://doi.org/10.1111/acel.70695 PubMed: https://pubmed.ncbi.nlm.nih.gov/42698366/
Educational material; it does not replace individual medical advice.